Pimasertib
- Generic Name
- Pimasertib
- Drug Type
- Small Molecule
- Chemical Formula
- C15H15FIN3O3
- CAS Number
- 1236699-92-5
- Unique Ingredient Identifier
- 6ON9RK82AL
- Background
Pimasertib is under investigation in clinical trial NCT01378377 (Combination Trial of Pimasertib (MSC1936369B) With Temsirolimus).
Oral SAR245408 (XL147) and Oral MSC1936369B in Patients With Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2011-05-20
- Last Posted Date
- 2016-04-01
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 18
- Registration Number
- NCT01357330
- Locations
- 🇺🇸
Investigational Site Number 840001, Boston, Massachusetts, United States
🇺🇸Investigational Site Number 840002, Boston, Massachusetts, United States
🇺🇸Investigational Site Number 840003, Nashville, Tennessee, United States
MEK Inhibitor MSC1936369B Plus FOLFIRI in Second Line K-Ras Mutated Metastatic Colorectal Cancer (mCRC)
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2010-03-11
- Last Posted Date
- 2016-10-19
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 16
- Registration Number
- NCT01085331
- Locations
- 🇪🇸
Research Site, Barcelona, Spain
Trial of Gemcitabine With or Without MSC1936369B in Pancreatic Cancer
- Conditions
- Pancreatic Adenocarcinoma
- Interventions
- First Posted Date
- 2009-11-19
- Last Posted Date
- 2017-07-13
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 141
- Registration Number
- NCT01016483
- Locations
- 🇺🇸
For Recruiting Locations in the United States, please Contact U.S. Medical Information, Rockland, Massachusetts, United States
🇩🇪For Recruiting Locations outside the United States, Please contact the Merck KGaA Communication Center, Darmstadt, Germany
Trial of MSC1936369B in Subjects With Solid Tumors
- First Posted Date
- 2009-09-23
- Last Posted Date
- 2018-10-23
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 182
- Registration Number
- NCT00982865
- Locations
- 🇫🇷
Hopital Saint Louis, Paris, France
🇦🇺Westmead Hospital, Westmead, Australia
🇫🇷Centre Eugène Marquis, Rennes, France
Trial of Pimasertib in Hematological Malignancies
- Conditions
- Leukemia, Myeloid, AcuteHematologic Neoplasms
- Interventions
- First Posted Date
- 2009-08-12
- Last Posted Date
- 2017-08-21
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 81
- Registration Number
- NCT00957580
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.